[시장보고서]구강건조증 치료제 시장 : 산업 규모, 점유율, 동향, 기회 및 예측, 유형별(OTC, 처방), 제품별(타액 분비 촉진제, 타액 대용품, 치약제), 지역별 및 경쟁별(2020-2030년)

구강건조증 치료제 시장 : 산업 규모, 점유율, 동향, 기회 및 예측, 유형별(OTC, 처방), 제품별(타액 분비 촉진제, 타액 대용품, 치약제), 지역별 및 경쟁별(2020-2030년)

Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region & Competition, 2020-2030F

상품코드 : 1703488

리서치사 : TechSci Research

발행일 : 2025년 04월

페이지 정보 : 영문 180 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,444,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,877,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,457,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 구강건조증 치료제 시장 규모는 2024년 21억 5,000만 달러로 평가되었고, 2030년까지 연평균 성장률(CAGR) 3.75%로 꾸준히 성장할 것으로 예상됩니다. 이 시장에는 구강건조증(일반적으로 구강건조증)의 증상을 관리하고 완화하기 위한 다양한 제품 및 치료법이 포함됩니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	21억 5,000만 달러
시장 규모 : 2030년	26억 9,000만 달러
CAGR : 2025-2030년	3.75%
급성장 부문	OTC
최대 시장	북미

구강건조증은 타액선 기능의 저하 또는 부재를 특징으로 하는 병태로 타액 분비량이 감소하는 질환입니다. 약물 부작용, 만성 질환, 방사선 치료, 자연적 노화 과정 등 다양한 요인에 의해 발생합니다.

주요 시장 성장 촉진요인

고령화 인구 증가

주요 시장 이슈

인지도 저하와 과소진단

주요 시장 동향

맞춤의료와 표적치료 접근법

영문목차

Global Xerostomia Therapeutics Market was valued at USD 2.15 billion in 2024 and is expected to register steady growth, projecting a compound annual growth rate (CAGR) of 3.75% through 2030. This market encompasses a range of products and treatments aimed at managing and alleviating the symptoms of xerostomia-commonly referred to as dry mouth.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.15 Billion
Market Size 2030	USD 2.69 Billion
CAGR 2025-2030	3.75%
Fastest Growing Segment	OTC
Largest Market	North America

Xerostomia is a condition characterized by diminished or absent salivary gland function, resulting in reduced saliva production. It can be caused by a variety of factors, including side effects of medications, chronic illnesses, radiation therapy, and the natural aging process.

Key Market Drivers

Growing Aging Population

The increasing global aging population is a primary driver for the expansion of the xerostomia therapeutics market. By 2050, approximately 80% of the world's elderly population is projected to reside in low- and middle-income countries-marking a substantial demographic shift with far-reaching economic and healthcare implications.

The pace of population aging is accelerating, creating both challenges and new opportunities within the healthcare sector. Notably, in 2020, the global population aged 60 and above exceeded the number of children under the age of five for the first time. Between 2015 and 2050, the proportion of individuals aged 60+ is expected to nearly double from 12% to 22%, emphasizing the urgent need for age-responsive healthcare solutions and infrastructure.

Xerostomia is particularly prevalent among older adults due to age-related decline in salivary gland function, which reduces saliva production. This not only impacts seniors' comfort and quality of life but also increases their susceptibility to oral infections and dental problems. Consequently, the elderly represent a growing and high-priority target group for xerostomia therapeutics.

Prevalence estimates for xerostomia in the general population vary widely, ranging from 0.9% to 64.8%, but the condition is significantly more common among older individuals-affecting approximately 30% of those over 65 and up to 40% of those over 80. In addition, seniors are more likely to be prescribed multiple medications for chronic conditions such as hypertension, diabetes, and cardiovascular disease, many of which list dry mouth as a common side effect. This further increases the incidence of xerostomia in older adults and, in turn, drives demand for effective treatment options to alleviate symptoms and improve adherence to long-term medication regimens.

Key Market Challenges

Limited Awareness and Underdiagnosis

One of the primary challenges facing the xerostomia therapeutics market is the widespread underdiagnosis of the condition. Because dry mouth often appears as a secondary symptom of other diseases or medication use, it is frequently overlooked in clinical settings.

Healthcare professionals may not always recognize xerostomia as a standalone issue, which can delay diagnosis and treatment. Additionally, many individuals experiencing dry mouth are unaware that the condition is medically treatable. Symptoms are often mistaken as normal aspects of aging or expected medication side effects, leading patients to forgo medical consultation. This lack of awareness-both among healthcare providers and the general public-poses a barrier to market growth.

Key Market Trends

Personalized Medicine and Targeted Therapeutic Approaches

A notable trend within the xerostomia therapeutics market is the shift toward personalized medicine. Advances in genomics and molecular science are providing deeper insights into the genetic and biological mechanisms that contribute to xerostomia in individual patients, enabling the development of more precise and effective treatments.

Pharmacogenomics-the study of how genetic variations influence drug response-is becoming increasingly important in tailoring xerostomia therapies. This approach allows clinicians to identify the most suitable treatment options for individual patients, thereby minimizing ineffective treatments and improving outcomes.

Ongoing research is also focused on identifying biomarkers associated with xerostomia, which may facilitate early diagnosis and aid in the selection of optimal treatment strategies. These developments hold significant promise for enhancing therapeutic efficacy and offering more targeted, personalized care to patients suffering from dry mouth.

Key Market Players

GlaxoSmithKline plc
Church & Dwight Co., Inc.
Colgate-Palmolive Company
Hikma Pharmaceuticals PLC
Pendopharm
Sun Pharmaceuticals Industries Ltd
Lupin Pharmaceuticals, Inc.
Pfizer, Inc.
Parnell Pharmaceuticals, Inc.
Acacia Pharma

Report Scope:

In this report, the Global Xerostomia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia Therapeutics Market, By Type:

OTC
Prescription

Xerostomia Therapeutics Market, By Product:

Salivary Stimulants
Salivary Substitutes
Dentifrices

Xerostomia Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia Therapeutics Market.

Available Customizations:

Global Xerostomia Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Xerostomia Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (OTC, Prescription)
- 5.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Xerostomia Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Product
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Xerostomia Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Product
- 6.3.2. Canada Xerostomia Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Product
- 6.3.3. Mexico Xerostomia Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Product

7. Europe Xerostomia Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Product
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Xerostomia Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Product
- 7.3.2. United Kingdom Xerostomia Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Product
- 7.3.3. Italy Xerostomia Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Product
- 7.3.4. France Xerostomia Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Product
- 7.3.5. Spain Xerostomia Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Product

8. Asia-Pacific Xerostomia Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Product
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Xerostomia Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Product
- 8.3.2. India Xerostomia Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Product
- 8.3.3. Japan Xerostomia Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Product
- 8.3.4. South Korea Xerostomia Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Product
- 8.3.5. Australia Xerostomia Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Product

9. South America Xerostomia Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Product
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Xerostomia Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Product
- 9.3.2. Argentina Xerostomia Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Product
- 9.3.3. Colombia Xerostomia Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Product

10. Middle East and Africa Xerostomia Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Product
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Xerostomia Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Product
- 10.3.2. Saudi Arabia Xerostomia Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Product
- 10.3.3. UAE Xerostomia Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Product

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Xerostomia Therapeutics Market: SWOT Analysis

14. Competitive Landscape

14.1. GlaxoSmithKline plc
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Church & Dwight Co., Inc.
14.3. Colgate-Palmolive Company
14.4. Hikma Pharmaceuticals PLC
14.5. Pendopharm
14.6. Sun Pharmaceuticals Industries Ltd
14.7. Lupin Pharmaceuticals, Inc.
14.8. Pfizer, Inc.
14.9. Parnell Pharmaceuticals, Inc.
14.10.Acacia Pharma.

한글목차

주요 시장 성장 촉진요인

주요 시장 이슈

주요 시장 동향

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 구강건조증 치료제 시장 전망

제6장 북미의 구강건조증 치료제 시장 전망

제7장 유럽의 구강건조증 치료제 시장 전망

제8장 아시아태평양의 구강건조증 치료제 시장 전망

제9장 남미의 구강건조증 치료제 시장 전망

제10장 중동 및 아프리카의 구강건조증 치료제 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 구강건조증 치료제 시장 : SWOT 분석

제14장 경쟁 구도

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항